Antibody Therapies for Large B-Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Large B-cell lymphomas (LBCLs) are aggressive yet curable lymphoproliferative diseases.
• Relapsed/refractory (R/R) LBCL presents a significant unmet clinical need.
• LBCLs express pan-B cell surface antigens, offering numerous druggable targets.

Purpose of the Study:

• To review antilymphoma monoclonal antibodies (mAbs) for LBCL treatment.
• To focus on the efficacy and safety of approved and developing mAbs.
• To discuss future perspectives in R/R LBCL management.

Main Methods:

• Review of scientific literature on monoclonal antibodies in LBCL.
• Analysis of efficacy and safety data for various mAb types.
• Exploration of novel therapeutic strategies and ongoing clinical trials.

Main Results:

• Novel mAbs, including naked mAbs, radioimmunoconjugates, antibody-drug conjugates, checkpoint inhibitors, and bispecific antibodies, have advanced R/R LBCL treatment.
• Anti-CD20 mAb rituximab remains a key therapy, with new mAbs showing remarkable efficacy in monotherapy and combination regimens.
• Ongoing studies aim to integrate these mAbs into frontline therapy or as chemotherapy-free options.

Conclusions:

• Monoclonal antibodies represent a significant therapeutic advance for R/R LBCL.
• Further research and clinical trials are crucial to optimize mAb use in LBCL treatment.
• Novel mAbs offer hope for improved outcomes in elderly or unfit patients and frontline settings.